JP4750999B2 - 核因子κＢ誘導因子 - Google Patents

核因子κＢ誘導因子 Download PDF

Info

Publication number
JP4750999B2
JP4750999B2 JP2001572589A JP2001572589A JP4750999B2 JP 4750999 B2 JP4750999 B2 JP 4750999B2 JP 2001572589 A JP2001572589 A JP 2001572589A JP 2001572589 A JP2001572589 A JP 2001572589A JP 4750999 B2 JP4750999 B2 JP 4750999B2
Authority
JP
Japan
Prior art keywords
nfif
expression
vector
nfκb
gene
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2001572589A
Other languages
English (en)
Japanese (ja)
Other versions
JP2003529360A5 (enExample
JP2003529360A (ja
Inventor
ジューン・カプロウ
トーマス・ホーズ
マリー・ロジエ
パトリス・デネフル
Original Assignee
アベンティス・ファーマスーティカルズ・インコーポレイテツド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB0018307.9A external-priority patent/GB0018307D0/en
Application filed by アベンティス・ファーマスーティカルズ・インコーポレイテツド filed Critical アベンティス・ファーマスーティカルズ・インコーポレイテツド
Publication of JP2003529360A publication Critical patent/JP2003529360A/ja
Publication of JP2003529360A5 publication Critical patent/JP2003529360A5/ja
Application granted granted Critical
Publication of JP4750999B2 publication Critical patent/JP4750999B2/ja
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702—Regulators; Modulating activity
    • C07K14/4705—Regulators; Modulating activity stimulating, promoting or activating activity
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Wood Science & Technology (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Biophysics (AREA)
  • Plant Pathology (AREA)
  • Rheumatology (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Urology & Nephrology (AREA)
  • Physics & Mathematics (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Toxicology (AREA)
  • Pain & Pain Management (AREA)
  • Microbiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
JP2001572589A 2000-03-31 2001-04-02 核因子κＢ誘導因子 Expired - Fee Related JP4750999B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US19390500P 2000-03-31 2000-03-31
US60/193,905 2000-03-31
GB0018307.9 2000-07-26
GBGB0018307.9A GB0018307D0 (en) 2000-07-26 2000-07-26 Polypeptides
PCT/US2001/010719 WO2001074900A2 (en) 2000-03-31 2001-04-02 Nuclear factor kb inducing factor

Publications (3)

Publication Number Publication Date
JP2003529360A JP2003529360A (ja) 2003-10-07
JP2003529360A5 JP2003529360A5 (enExample) 2008-05-15
JP4750999B2 true JP4750999B2 (ja) 2011-08-17

Family

ID=26244722

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2001572589A Expired - Fee Related JP4750999B2 (ja) 2000-03-31 2001-04-02 核因子κＢ誘導因子

Country Status (14)

Country Link
EP (1) EP1290023B1 (enExample)
JP (1) JP4750999B2 (enExample)
KR (1) KR100811571B1 (enExample)
AT (1) ATE486089T1 (enExample)
AU (1) AU4793101A (enExample)
CA (1) CA2404688C (enExample)
DE (1) DE60143354D1 (enExample)
DK (1) DK1290023T3 (enExample)
IL (3) IL151987A0 (enExample)
MX (1) MXPA02009481A (enExample)
NO (1) NO331972B1 (enExample)
NZ (1) NZ521786A (enExample)
PT (1) PT1290023E (enExample)
WO (1) WO2001074900A2 (enExample)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN117534753B (zh) * 2023-12-07 2024-05-10 北京博奥森生物技术有限公司 一种诱导高性能NF-κB多克隆抗体多肽及其应用

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3486053T3 (de) 1983-10-20 2004-01-08 The Research Foundation Of State University Of New York Regulierung von Gen-Expression durch Translationshemmung unter Verwendung von m-RNS hinderndem Komplementär-RNS.
FR2573436B1 (fr) 1984-11-20 1989-02-17 Pasteur Institut Adn recombinant comportant une sequence nucleotidique codant pour un polypeptide determine sous le controle d'un promoteur d'adenovirus, vecteurs contenant cet adn recombinant, cellules eucaryotes transformees par cet adn recombinant, produits d'excretion de ces cellules transformees et leurs applications, notamment a la constitution de vaccins
US5585362A (en) 1989-08-22 1996-12-17 The Regents Of The University Of Michigan Adenovirus vectors for gene therapy
WO1992015680A1 (en) 1991-03-06 1992-09-17 Board Of Regents, The University Of Texas System Methods and compositions for the selective inhibition of gene expression
WO1993008845A1 (en) 1991-11-08 1993-05-13 Massachusetts Institute Of Technology Localized oligonucleotide therapy
AU687736B2 (en) 1992-05-11 1998-03-05 Ribozyme Pharmaceuticals, Inc. Method and reagent for inhibiting viral replication
EP0786522A2 (en) 1992-07-17 1997-07-30 Ribozyme Pharmaceuticals, Inc. Enzymatic RNA molecules for treatment of stenotic conditions
EP0651805B1 (en) 1992-07-17 2006-12-13 Dana Farber Cancer Institute Method of intracellular binding of target molecules
CA2592997A1 (en) 1992-12-03 1994-06-09 Genzyme Corporation Pseudo-adenovirus vectors
FR2705686B1 (fr) 1993-05-28 1995-08-18 Transgene Sa Nouveaux adénovirus défectifs et lignées de complémentation correspondantes.
FR2706486B1 (fr) 1993-06-16 1995-09-01 Rhone Poulenc Rorer Sa Séquences nucléiques, vecteurs les contenant, compositions pharmaceutiques et utilisations thérapeutiques.
ES2310924T3 (es) 1993-07-13 2009-01-16 Centelion Vectores adenovirales defectivos y utilizacion en terapia genica.
IL116816A (en) 1995-01-20 2003-05-29 Rhone Poulenc Rorer Sa Cell for the production of a defective recombinant adenovirus or an adeno-associated virus and the various uses thereof
WO1997037020A1 (en) * 1996-04-01 1997-10-09 Genentech, Inc. Apo-2li and apo-3 apoptosis polypeptides
US6235512B1 (en) * 1997-07-01 2001-05-22 Tularik Inc. IKK-α proteins, nucleic acids and methods
US6132964A (en) * 1998-02-06 2000-10-17 Incyte Pharmaceuticals, Inc. Hydrolase enzymes
AU4187499A (en) * 1998-05-14 1999-11-29 Chiron Corporation Human genes and gene expression products v
GB9814036D0 (en) * 1998-06-29 1998-08-26 Univ Dundee Materials and methods relating to the induction of apoptosis in target cells
US6077672A (en) * 1998-08-28 2000-06-20 Isis Pharmaceuticals Inc. Antisense modulation of TRADD expression
CN1302897A (zh) * 1999-10-28 2001-07-11 上海博容基因开发有限公司 一种新的多肽——人酸性鞘磷酯酶相似的磷酸二酯酶21和编码这种多肽的多核苷酸
CA2402563A1 (en) * 1999-12-23 2001-07-26 Hyseq, Inc. Novel nucleic acids and polypeptides
EP1358347A2 (en) * 2000-04-05 2003-11-05 Incyte Genomics, Inc. Genes expressed in foam cell differentiation
EP1358349A2 (en) * 2000-06-05 2003-11-05 Avalon Pharmaceuticals Cancer gene determination and therapeutic screening using signature gene sets

Also Published As

Publication number Publication date
IL151987A (en) 2010-12-30
AU4793101A (en) 2001-10-15
HK1053312A1 (en) 2003-10-17
DK1290023T3 (da) 2011-02-14
EP1290023A2 (en) 2003-03-12
KR100811571B1 (ko) 2008-03-10
IL151987A0 (en) 2003-04-10
NO331972B1 (no) 2012-05-14
JP2003529360A (ja) 2003-10-07
KR20020087459A (ko) 2002-11-22
WO2001074900A9 (en) 2003-03-06
CA2404688C (en) 2012-07-31
CA2404688A1 (en) 2001-10-11
WO2001074900A3 (en) 2002-05-02
WO2001074900A2 (en) 2001-10-11
PT1290023E (pt) 2011-01-05
NO20024656D0 (no) 2002-09-27
IL198132A0 (en) 2011-08-01
EP1290023B1 (en) 2010-10-27
MXPA02009481A (es) 2004-05-14
NZ521786A (en) 2004-07-30
NO20024656L (no) 2002-11-28
DE60143354D1 (de) 2010-12-09
ATE486089T1 (de) 2010-11-15

Similar Documents

Publication Publication Date Title
US6300484B1 (en) DNA encoding DP. 75 and a process for its use
WO1999009049A1 (en) Hypoxia-regulated genes
AU5810999A (en) Sequences characteristic of hypoxia-regulated gene transcription
JPH1175873A (ja) 新規化合物
US7329741B2 (en) Polynucleotides that hybridize to DP-75 and their use
US8623831B2 (en) Nuclear factor κB inducing factor
JP4750999B2 (ja) 核因子κＢ誘導因子
US6586581B1 (en) Prolactin regulatory element binding protein and uses thereof
AU2001247931B2 (en) Nuclear factor kB inducing factor
JP2002542826A (ja) 腫瘍壊死因子α（ＴＮＦ−α）シグナル伝達経路のインヒビターとして働くＴＲＡＦ２の改変体
ES2354811T3 (es) Factor inductor del factor nuclear kb.
AU2001247931A1 (en) Nuclear factor kB inducing factor
JP4548938B2 (ja) Ｍｅｋｋ１（セリントレオニンキナーゼ）相互作用性ｆｈａ（フォークヘッド結合ドメイン）タンパク質１（ｍｉｆ１）
HK1053312B (en) Nuclear factor kb inducing factor
US7332593B2 (en) Variants of TRAF2 which act as an inhibitor of TNF-alpha (TNFα) signaling pathway
JPH11178583A (ja) 新規化合物

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20080331

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20080331

RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20090929

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20101005

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20101227

RD02 Notification of acceptance of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7422

Effective date: 20101227

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20110111

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20110404

A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20110426

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20110520

R150 Certificate of patent or registration of utility model

Free format text: JAPANESE INTERMEDIATE CODE: R150

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20140527

Year of fee payment: 3

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

LAPS Cancellation because of no payment of annual fees